Difficulties in the Diagnosis of Inclusion Body Myositis-Case Report

1. Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000;55(9):1385–7.10.1212/WNL.55.9.1385Search in Google Scholar

2. Dobloug GC, Antal EA, Sveberg L, Garen T, Bitter H, Stjarne J, et al. High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study. Eur J Neurol 2015;22(4):672-e41.10.1111/ene.1262725530508Search in Google Scholar

3. Dalakas MC. Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006;2(8):437-47.10.1038/ncpneuro026116932602Open DOISearch in Google Scholar

4. Needham M, Mastaglia FL. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clin Neurophysiol 2016 Mar;127(3):1764-73.10.1016/j.clinph.2015.12.01126778717Search in Google Scholar

5. Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry 2013;84:1240–6.10.1136/jnnp-2013-30569023864699Open DOISearch in Google Scholar

6. Hilton-Jones D, Brady S. Diagnostic criteria for inclusion body myositis.. J Intern Med. 2016;280(1):52-62.10.1111/joim.1248027027255Search in Google Scholar

7. Catalán M, Selva-O’Callaghan A, Grau J.M. Diagnosis and classification of sporadic inclusion body myositis (sIBM). Autoimmunity Reviews 2014; 13: 363–366.2442418510.1016/j.autrev.2014.01.01624424185Search in Google Scholar

8. Rose MR, Working Group ENMCIBM. 188th ENMC International Workshop: inclusion body myositis. Neuromuscul Disord. 2013;23:1044–55.Search in Google Scholar

9. Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open. 2014;4:e004552.10.1136/bmjopen-2013-004552401081624776709Search in Google Scholar

10. Larue S, Maisonobe T, Benveniste O, Chapelon-Abric C, Lidove O, Papo T et al. Distal muscle involvement in granulomatous myositis can mimic inclusion body myositis. J Neurol Neurosurg Psychiatry 2011; 82: 674–7.10.1136/jnnp.2009.19075120562458Search in Google Scholar

11. Schellenberg KL, Johnston WS, Kalra S, Resch L, Johnson ES. Inclusion body myositis masquerading as amyotrophic lateral sclerosis. Can J Neurol Sci. 2010;37(5):687–91.10.1017/S031716710001091X21059520Open DOISearch in Google Scholar

12. Dalakas MC. Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol 2003; 23: 199–206.10.1055/s-2003-4113612894385Search in Google Scholar

13. Quick A, Tandan R. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep. 2011;13(3):192-8. doi: 10.1007/s11926-011-0171-0.10.1007/s11926-011-0171-021503696Search in Google Scholar

14. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009-15. doi: 10.1212/WNL.0b013e31824de293.10.1212/WNL.0b013e31824de29322454268Open DOISearch in Google Scholar

15. Donofrio PD, Berger A, Brannagan 3rd TH, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM Ad Hoc Committee. Muscle Nerve. 2009;40:890–900.10.1002/mus.2143319768755Open DOISearch in Google Scholar